172 related articles for article (PubMed ID: 37096560)
1. Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines.
Son S; Elkamhawy A; Gul AR; Al-Karmalawy AA; Alnajjar R; Abdeen A; Ibrahim SF; Alshammari SO; Alshammari QA; Choi WJ; Park TJ; Lee K
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2202358. PubMed ID: 37096560
[TBL] [Abstract][Full Text] [Related]
2. New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors.
Ezelarab HAA; Abd El-Hafeez AA; Ali TFS; Sayed AM; Hassan HA; Beshr EAM; Abbas SH
Bioorg Chem; 2024 Apr; 145():107234. PubMed ID: 38412650
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
7. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
11. Quinazolin-4(3
Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
[TBL] [Abstract][Full Text] [Related]
12. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
13. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies.
Hawas SS; El-Sayed SM; Elzahhar PA; Moustafa MA
Bioorg Chem; 2023 Dec; 141():106874. PubMed ID: 37769524
[TBL] [Abstract][Full Text] [Related]
14. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis.
El-Azab AS; Abdel-Aziz AA; AlSaif NA; Alkahtani HM; Alanazi MM; Obaidullah AJ; Eskandrani RO; Alharbi A
Bioorg Chem; 2020 Nov; 104():104345. PubMed ID: 33142413
[TBL] [Abstract][Full Text] [Related]
16. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
17. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Sabry MA; Ghaly MA; Maarouf AR; El-Subbagh HI
Eur J Med Chem; 2022 Nov; 241():114661. PubMed ID: 35964425
[TBL] [Abstract][Full Text] [Related]
18. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR/HER2 dual-target inhibitors.
Jiao X; Zhang Q; Zhang Y; Shao J; Ding L; Tang C; Feng B
Bioorg Med Chem Lett; 2022 Jul; 67():128703. PubMed ID: 35364239
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]